P&R OPTIMISED TRIAL DESIGN

PRODUCT X’s trial design was optimized from the P&R perspective via in-depth primary research with payer stakeholders in FRA and GER.

FRDE

OBJECTIVE

  • To assess the P&R implications of using different registrational trial scenarios to launch PRODUCT X in relapsed / refractory multiple myeloma in FRA and GER
APPROACH

  • Comprehensive P&R landscape assessment, both of multiple myeloma and brand-brand analogues, including an HTA analysis
  • Workshop to align on discussion guide and stimulation materials with core team
  • Execution of primary research programme, which consisted of 4 payer:KOL dyads per market
  • Synthesis of primary and secondary research findings into recommendations for registrational trial design to optimize PRODUCT X pricing and access
KEY DELIVERABLES

  • Multiple myeloma and brand-brand combinations landscape assessment (.PPT)
  • Summary of primary research findings (.PPT)
  • Anticipated P&R barriers for PRODUCT X by market (.PPT)
  • Recommendations for trial design for optimal pricing / market access in FRA, GER (.PPT)
CLIENT FEEDBACK

  • Our team was invited to consult on preparations for the early advice process for this asset with the G-BA
  • A follow-on thought piece for anticipated hurdles for brand-brand combinations in the USA and EU5 was commissioned